Special 301 Submission

Sickle Cell Community Encouraged to Share Perspective with FDA

02.07.14 | By

As highlighted in an earlier Catalyst post, PhRMA is partnering with Genetic Alliance on an exciting project to enhance patient engagement in the Food and Drug Administration’s (FDA) Patient-Focused Drug Development initiative. Genetic Alliance recently launched the first pilot program, partnering with four trusted organizations serving the sickle cell community.

Pilot Programs to Focus on Alzheimer’s Disease, Autoimmune Disorders and Type 2 Diabetes

Washington, D.C. (February 4, 2014) – The Pharmaceutical Research and Manufacturers of America (PhRMA) has joined the National Institutes of Health (NIH),  10 biopharmaceutical companies and several non-profit disease foundations in a partnership to transform the current model for developing new diagnostics and treatments by jointly identifying and validating promising biological targets of disease.

Public-Private Partnerships Key to Addressing Public Health Challenges

02.04.14 | By

NIH LogoA groundbreaking new partnership was announced earlier today by the National Institutes of Health (NIH).

Soaring to New Heights

01.31.14 | By

What does working in a lab have in common with flying an airplane? A great deal according to the next researcher highlighted in our “I am Research, Progress, Hope” series, Dowdy Jackson, head of the Antibody Drug Conjugate (ADC) Biology group at Agensys, an affiliate of Astellas.

2014: A Year of Action to Foster Innovation

01.30.14 | By

In his State of the Union, President Obama said, "A nation that goes all-in on innovation today will own the global economy tomorrow." We couldn't agree more.

From Space to Science

01.24.14 | By

This week at the STEM Saves Lives forum, we were fortunate enough to hear from the first woman of color to go into space. Now, we hear from a woman who considered taking a similar path, but instead decided to pursue a career in biopharmaceutical research.

Industry’s Efforts Impact More Than 1.6 Million Students in Past Five Years

WASHINGTON, D.C. (January 22, 2014) – Innovative biopharmaceutical companies and their corporate foundations are making significant contributions to U.S. science, technology, engineering and math (STEM) education through a broad range of local, state and national level programs and initiatives aimed at elementary through post-secondary education, according to a first-of-its-kind report by the Battelle Technology Partnership Practice.

Addressing Gaps in U.S. STEM Education

01.22.14 | By

It’s been widely reported that the United States has a science, technology, engineering and math (STEM) education problem. As we fall behind other countries in STEM proficiencies, our leadership in innovation across sectors is at risk. In the biopharmaceutical research industry, we are dependent on highly skilled workers with extensive STEM knowledge to develop novel, life-saving medicines and diagnostics.

backgrounder - stem


Subscribe to RSS - Innovation